OC-0272: Twice daily reirradiation with cetuximab vs once daily chemoRT after surgery in head and neck cancer
نویسندگان
چکیده
منابع مشابه
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
This study compared the bronchodilator effects of tiotropium, formoterol and both combined in chronic obstructive pulmonary disease (COPD). A total of 71 COPD patients (mean forced expiratory volume in one second (FEV1) 37% predicted) participated in a randomised, double-blind, three-way, crossover study and received tiotropium 18 microg q.d., formoterol 12 microg b.i.d. or both combined q.d. f...
متن کاملOnce-daily indacaterol vs twice-daily salmeterol for COPD: a placebo- controlled comparison
200 words] Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator, recently approved in Europe for the treatment of COPD. This study set out to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β2-agonist, salmeterol, as an active control. Patients with moderate-to-severe COPD were randomized to 6 months double-blind ...
متن کاملComparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
BACKGROUND A prolonged-release formulation of tacrolimus (Tacrolimus QD) was developed to allow once-daily dosing and to have similar safety and efficacy profiles to twice-daily tacrolimus (Tacrolimus BID). This study compared the pharmacokinetics (PK) and renal pathology by protocol biopsy in de novo living kidney transplant recipients treated with either low-dose Tacrolimus QD or Tacrolimus B...
متن کاملOnce-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
OBJECTIVE This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas). RESEARCH DESIGN AND METHODS Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma gl...
متن کاملTwice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
INTRODUCTION Bromfenac is a well-known topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) that is commercialized in the USA and other regions of the world. A new formulation, 0.075% bromfenac in DuraSite®, was developed to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery. We hypothesized that efficacy and safety would be enhanced with ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2018
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(18)30582-6